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no significant correlation was found between the TBR in 
the left and right atrial wall and blood glucose levels. 18F-
FDG PET/CT performed under routine conditions did not 
detect a significant difference in inflammatory activity in 
the left or right atrium between patients with and without 
AF. Contrary to previous reports, these results therefore do 
not clearly support a role for ongoing atrial inflammation 
in patients with AF. Prospective clinical studies using myo-
cardial glucose uptake suppression strategies may be help-
ful to clarify these issues.
Keywords Atrial fibrillation · Inflammation · Positron 
emission tomography · Cardiac imaging
Introduction
Atrial fibrillation (AF) is the most common arrhythmia in 
industrialized countries with an increasing burden of mor-
bidity [1–3]. Electrical and structural remodelling of the 
atria promotes the development, maintenance and progres-
sion of AF [4–6]. Remodelling in AF is accompanied by 
atrial fibrosis, changes in cardiac autonomous innervation 
and inflammation. Different imaging strategies have been 
employed to visualize atrial fibrosis and cardiac autono-
mous innervation. These imaging approaches have shown 
to provide additional information on the individual risk 
of AF recurrence and therapy outcome. Imaging of atrial 
fibrosis [7] and molecular imaging of autonomous inner-
vation [8] might in fact be helpful to better select patients 
for antiarrhythmic therapies. Inflammation is less well 
characterized in AF. However, clinical evidence suggests 
a causative link between inflammation and the occurrence 
of AF. A number of inflammatory markers including C 
reactive protein (CRP) and Interleukin-6 have been shown 
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to correlate with the incidence and recurrence rates of AF 
[9–11]. For instance, C reactive protein (CRP) has been 
demonstrated to correlate with the incidence of AF and the 
recurrence after cardioversion [12, 13].
Based on these observations, it has been speculated that 
inflammation based therapies could even offer novel thera-
peutic options to patients suffering from AF [14, 15]. How-
ever, direct evidence of persistent inflammatory activity in 
the atria of AF patients is scarce. 18-Fluor-Deoxyglucose 
positron emission tomography (18F-FDG PET) has been 
successfully employed to visualize inflammatory pro-
cesses. Data from a small clinical study showed a higher 
inflammatory activity in adipose tissue determined by PET/
CT imaging in patients with paroxysmal AF compared to 
patients without atrial fibrillation [16]. Mazurek et al. [16] 
demonstrated higher standardized uptake values (SUV) of 
the epicardial adipose tissue in the roof of the left atrium, 
in the atrioventricular groove and in the left main artery of 
patients with AF compared to the control group. Moreover, 
Kusayama et al. [17] claimed a higher inflammation activ-
ity of the epicardial adipose tissue around the left atrium in 
patients with atrial fibrillation compared to a control group 
without AF based on density measurements using cardiac 
computed tomography. Accordingly, we hypothesized that 
patients with AF have a higher inflammation activity in the 
atrial walls that could be detected and quantified by PET/
CT imaging. Here, we describe a series of 37 patients with 
AF and 37 control patients without AF who underwent 
PET/CT imaging for other clinical indications.
Patients and methods
We conducted a retrospective single-center study including 
18F-FDG PET/CT examinations performed between April 
2009 and September 2013 with a total of 74 patients. PET/
CT scans of patients referred to the Department of Nuclear 
Medicine for various clinical indications were analyzed. 
Based on ICD codes, all consecutive patients with a his-
tory of AF (n = 37 patients, 25 men; mean age 70 ± 7 years; 
21 patients with malignancies, 16 patients with systemic 
inflammation) were selected and compared to an age and 
sex matched control group with no history of AF (n = 37 
patients, 24 men; mean age 71 ± 7 years; 34 patients with 
malignancies, three patients with systemic inflamma-
tion). Among the patients in the AF group, 24 individuals 
suffered from paroxysmal forms of AF, 12 patients had 
chronic forms of AF (persistent or permanent AF). Three 
patients in the AF group and three patients in the control 
group suffered from Diabetes, four patients in the control 
group and eight patients in the AF group received an anti-
inflammatory medication at the time of the PET/CT scan. 
Dyslipidemia was present in 12 patients of the AF group 
and in two patients of the control group. A diagnosis of 
arterial hypertension was documented in 13 patients in 
the control group, while 20 patients in the AF group had a 
diagnosis of arterial hypertension.
The study was approved by the University of Münster 
Ethical Committee and Institutional Review Board. There-
fore, it has been performed in accordance with the ethical 
standards laid down in the 1964 Declaration of Helsinki 
and its later amendments. All patients gave their written 
informed consent for the PET examination.
Patient preparation and PET/CT examination
Details concerning the PET/CT procedures have been 
published elsewhere [18, 19]. To suppress physiological 
myocardial glucose uptake, all patients were studied after 
fasting for at least 6 h. Blood glucose levels at the time of 
18F-FDG application ranged from 76 to 172 mg/dL (mean 
110 ± 21 mg/dl). A body-weight—adapted activity of 18F-
FDG (5  MBq/kg of body weight) was injected intrave-
nously approximately 60 min before PET data acquisition 
(mean activity: 339 MBq ± 61 MBq, range 205–491 MBq). 
The scans were obtained using a hybrid PET/CT system 
(Biograph Sensation 16; Siemens Medical Solutions). Low-
dose CT of the entire area covered by PET (from skull base 
to the mid thigh level) was performed for attenuation cor-
rection in all patients. CT scans were obtained either on 
a 16-slice integrated in the PET/CT system, with a slice 
thickness of 1.0 or 0.75 mm. After completion of the CT 
scan, PET data were acquired for 3 min per bed position. 
PET images were reconstructed with attenuation correction 
using the standard manufacturer-supplied software.
All PET/CT scans were reviewed and analyzed by two 
nuclear medicine physicians, experienced in PET analysis, 
who were not aware of the diagnosis of atrial fibrillation. 
Image analysis was performed with the Siemens syngo.via 
software, version 2. 18F-FDG uptake was measured using 
the function Region-Of-Interest (ROI). 18F-FDG uptake 
was evaluated quantitatively by the calculation of standard-
ized uptake values (SUVmax and SUVmean) in the attenu-
ation-corrected images.
SUVs were obtained in the left and right atrial wall by 
placing 5 regions of interest (ROI) of equal size (10 mm2 
each) within the atrial walls, 5 ROIs (20 mm2 each) in the 
left ventricular wall and one ROI (250  mm2) in the right 
ventricular blood pool (Fig.  1). Special care was taken in 
excluding 18F-FDG uptake of neighboring organs. CT 
images were used for attenuation correction of the PET 
data and for anatomical correlation.
In order to correct for blood pool activity, target to back-
ground ratios (TBR) were determined in each patient by 
calculating the ratio of the mean of the 5 SUVmax in the 
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atrial wall or the mean of the 5 SUVmax in the left ven-
tricular wall, respectively, and the SUVmean of the right 
ventricular blood pool.
Continuous variables are presented as mean ± standard 
deviation, and categorical variables are expressed as fre-
quencies. Pearsons correlation coefficient was calculated 
for the evaluation of significant association between two 
parameters. A Kolmogorov–Smirnov test was performed 
for continous variables to test for normality. A Mann-Whit-
ney-U-test was conducted to compare two means, whereby 
statistical significance was assumed at p value < 0.05.
Data analysis was performed using SPSS 15.0 soft-
ware (IBM Corp, Armonk, NY) and Excel 2010 software 
(Microsoft Corp, Redmond, WA).
Results
TBR of the left atrial wall were slightly but not significantly 
higher in patients with AF compared to those without AF 
TBR left atrium 1.14 ± 0.29 (control group) and 1.21 ± 0.27 
(AF group, respectively; p = 0.85; Fig. 2a). A weak, albeit 
not significant difference was observed in signal intensities 
in the right atrial wall between patients in the AF and con-
trol group (TBR right atrium 0.96 ± 0.2 (control group) and 
1.14 ± 0.45 (AF group, respectively; p = 0.41; Fig.  2b)). 
TBR values of the left ventricular myocardium did not dif-
fer between the groups (p = 0.51).
In both groups, TBR of the left and right atrial walls 
showed a low to moderate correlation with TBR of the left 
ventricular myocardium (r = 0.35 and 0.36; p = 0.003 and 
p = 0.002, respectively; Fig. 3).
In order to investigate metabolic effects that could con-
ceal differences in signal intensities between the control 
and the AF group, we further analyzed serum blood glu-
cose values. Serum glucose levels were comparable among 
both groups (113 ± 23  mg/dl (control) vs. 106 ± 16  mg/dl 
(AF)). No significant correlation was found between the 
TBR in the left (r=−0.19; p = 0.12) and right (r=−0.12; 
p = 0.34) atrial wall and the blood glucose levels.
To rule out systemic inflammation as a potential con-
founder, patients with systemic inflammation were excluded 
in both groups and tumor patients (n = 21 (AF group) and 
n = 34 (control group)) were analyzed separately. Again, 
TBR values of the left atrial myocardium did not differ sig-
nificantly between the groups (TBR left atrium 1.14 ± 0.30 
Fig. 1  Representative images with selection of ROIs: a blood pool within the right ventricle; b in the lateral left ventricular wall; c, d in the 
atrial walls
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(control group) and 1.25 ± 0.30 (AF group, respectively), 
p = 0.22). Likewise, the TBR values of the right atrial 
myocardium did not display a significant difference (TBR 
right atrium 0.96 ± 0.19 (control group) and 1.21 ± 0.53 
(AF group, respectively), p = 0.12; not shown). Moreover, 
in order to decipher a possible association between the 
duration of atrial fibrillation and the inflammatory activity 
measured in the atria, patients with paroxysmal and chronic 
forms of AF were compared. However, a significant differ-
ence could not be observed (TBR left atrium 1.22 ± 0.27 
(paroxysmal AF) vs. 1.18 ± 0.29 (chronic forms of AF), 
p > 0.05).
Discussion
In this retrospective study, we observed a slightly higher 
18F-FDG uptake in the atrial walls of patients with AF. The 
direct comparison of atrial TBR values between the AF 
and control group did not reach the level of statistical sig-
nificance. It cannot be ruled out that the study of a larger 
cohort of AF and control patients would reveal statistically 
significant differences. However, the small absolute differ-
ences in 18F-FDG uptake argue against the presence of rel-
evant atrial inflammation in the patients of the AF group. 
Therefore, the PET/CT imaging data presented here do not 
Fig. 2  Target to background ratios of patients with and without atrial fibrillation of the left (a) and right (b) atrial wall shown as box plots
Fig. 3  Regression plots of the TBR of the atrial walls vs. TBR of the left ventricular myocardium: a left atrial wall; b right atrial wall
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clearly support an association between a higher inflamma-
tory activity and AF. However, the patients analyzed in this 
study were referred to the clinic for various indications, 
mostly malignancies and infections of unknown origin. For 
this reason, the patient collective in this retrospective study 
does not fully represent the population of AF patients. 
However, after exclusion of patients with systemic inflam-
mation, signal intensities in the atrial walls still did not dis-
play a significant difference.
Another limitation of the study is the lack of ECG data 
at the time of the scan. In fact, a time dependent associa-
tion between inflammation and the onset of atrial fibrilla-
tion cannot be ruled out. However, there was no significant 
difference in the inflammatory activity measured by PET/
CT when comparing patients with paroxysmal and chronic 
forms of atrial fibrillation.
Several converging lines of evidence suggest an impor-
tant role of inflammation in the complex chain of events 
eventually leading to the development of AF [20]. It is 
assumed that local inflammatory processes as well as sys-
temic inflammation can foster the development of AF. 
Arterial hypertension, obesity, and coronary artery disease 
have been discussed as sources of inflammation in patients 
with AF. In animals, arterial hypertension has been shown 
to promote atrial leucocyte infiltration, inflammation, 
atrial fibrosis and increased vulnerability to AF suggest-
ing a relationship between these factors [21]. Patients with 
obesity seem to have a higher risk for progression of AF 
[20]. Consistently, the pericardial adipose tissue has been 
shown to promote inflammation and atrial fibrillation [16, 
22]. Moreover, AF itself seems to promote inflammation 
[20, 21] and immune cells have been detected in the atria 
of patients with AF [20]. In fact, detecting inflammation in 
AF patients would help to develop tailored anti-inflamma-
tory strategies for the treatment and prevention of AF. Spe-
cifically, it could be determined whether specific AF patient 
subgroups could benefit from anti-inflammatory therapies.
PET(/CT) is an established imaging modality to detect 
local inflammation. However, the local detection of inflam-
mation by PET critically depends on the concentration 
and metabolic activity of immune cells within a given tis-
sue volume. Moreover, PET imaging has a limit of spa-
tial resolution [23]. In addition, both cardiac and respira-
tory motions further impair the spatial resolution, increase 
image noise and reduce PET signal. Therefore, low level 
inflammation in the atria and the surrounding tissues might 
not be detected adequately by PET/CT, and inflammatory 
“hot spots” might not be evenly distributed around the 
left or right atrium. Here, in order to record the complete 
inflammatory activity around the atria, numerous ROIs of 
equal size were used to determine myocardial tracer uptake. 
However, very small areas with higher inflammatory activ-
ity might still be missed by this image analysis approach. 
In addition, partial volume effects can influence quantita-
tive PET-analysis of small or thin structures. However, 
modern PET scanners as used in our study have a spatial 
resolution of up to 2  mm. Spill-over from the adjacent 
blood pool could be virtually excluded by CT-guided ROI 
placement. In fact, PET/CT has already been employed to 
detect inflammatory activity in AF patients. Mazurek et al. 
[16] claimed an association of pro-inflammatory activity 
of epicardial adipose tissue to the occurrence of AF. Of 
note, in contrast to our investigation, SUV measurements 
were not corrected for blood pool activity and small sin-
gle ROIs were used in that study. Moreover, the selection 
of ROI placement did not follow clear criteria. In our study, 
the activity in the atrial walls moderately correlated with 
the activity in the left ventricular myocardium. This obser-
vation suggests a generally increased myocardial glucose 
metabolism rather than a genuinely higher inflammatory 
activity in patients with AF.
Taken together, contrary to previous results, the pre-
sent data do not indicate a diagnostic value of 18F-FDG 
PET for the detection of inflammatory activity in the left 
and right atria of patients with a history of AF when per-
formed under routine conditions. Generally, the detection 
of inflammatory activity in the atria may be hampered by 
the physiological myocardial glucose metabolism. Thus, 
prospective clinical imaging studies of a larger homogene-
ous cohort of AF patients in the absence of systemic dis-
ease and relevant comorbidities using dedicated techniques 
for the suppression of physiological myocardial glucose 
uptake such as preparation with a “high fat low carb” diet 
and/or the administration of heparin prior to PET scanning 
should be considered.
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